Overexpression of key complement regulators in glioblastoma.
Overview
- Division of Clinical Sciences, Department of Neurosurgery, Rausing Laboratory, Lund University, Lund, Sweden
- Department of Neurosurgery, Skåne University Hospital, Lund, Sweden
Abstract
Background: Glioblastoma (GBM) is the most prevalent and malignant primary brain tumor in adults. While immune evasion is a well-recognized driver of GBM progression and a major obstacle for efficient immunotherapy, the role of the complement system remains underexplored. C1-inhibitor (C1-INH), a regulator of complement activation, was recently found overexpressed in GBM. We therefore hypothesized that GBM overexpresses additional complement regulators beyond C1-INH and the present work aimed to identify these.
Method: Gene expression of complement inhibitors, the complement regulator pentraxin-3 (PTX3), and complement proteins was analyzed across nine publicly available transcriptomic datasets. Within each dataset, statistical comparisons were performed between sample groups for each gene. Differentially expressed complement inhibitors were validated at the protein level by immunostaining in the rat GBM cell line NS1 and patient derived GBM tissue.
Results: CFI, encoding factor I, was significantly overexpressed in GBM compared to non-tumoral brain, while THBD and CFH, encoding thrombomodulin and factor H, displayed moderate overexpression. SERPING1, encoding C1-INH, was also upregulated, confirming previous findings. Immunostaining confirmed the expression of these inhibitors in vitro as well as in human glioblastoma tissue. Additionally, PTX3 and early complement proteins were significantly overexpressed in GBM, while levels of C5 and downstream components were comparable to normal brain.
Conclusions: Our findings indicate that the GBM tumor overexpresses a specific set of complement regulators and components of the complement cascade, possibly inhibiting an efficient anti-tumoral immune response. Further investigations of these regulators as potential therapeutical targets in GBM are therefore highly warranted.
Reproduced under the paper's license (CC BY), from the paper cited above.
Code
The paper links to its data, not to its authors' code: see the Data section.
Tracing map
A tracing map links a paper to the code its authors published: this paper has none, so it has no map.
Data
Datasets cited
- geo:GSE263588 — at NCBI GEO; found in the references
Data Availability
Direct links to each dataset are as follows: • GSE263588: https://
Reproduced under the paper's license (CC BY), from the paper cited above.
Versions
The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.
Version 1, 28 September 2026: the first record
Recorded: type, language, journal, volume, issue, pages, dates, 5 authors, 15 MeSH terms, 2 funders, 62 references.
Cite
This paper
Blomberg, L., Raba, L., Bengzon, J., Osther, K., & Nittby Redebrandt, H. (2026). Overexpression of key complement regulators in glioblastoma. PloS one, 21(5), e0349101. https://
BibTeX
@article{blomberg2026ove
author = {Blomberg, Linnea and Raba, Leonora and Bengzon, Johan and Osther, Kurt and Nittby Redebrandt, Henrietta},
title = {{Overexpression of key complement regulators in glioblastoma}},
journal = {PloS one},
year = {2026},
month = may,
volume = {21},
number = {5},
pages = {e0349101},
publisher = {PLOS},
issn = {1932-6203},
doi = {10.1371/
url = {https://
pmid = {42139305},
pmcid = {PMC13178988}
}
RIS
TY - JOUR
AU - Blomberg, Linnea
AU - Raba, Leonora
AU - Bengzon, Johan
AU - Osther, Kurt
AU - Nittby Redebrandt, Henrietta
TI - Overexpression of key complement regulators in glioblastoma
T2 - PloS one
J2 - PLoS One
PY - 2026
DA - 2026/
VL - 21
IS - 5
SP - e0349101
SN - 1932-6203
PB - PLOS
DO - 10.1371/
UR - https://
LA - en
ER -
CSL-JSON
{
"id": "10.1371/
"type": "article-journal",
"title": "Overexpression of key complement regulators in glioblastoma",
"container-title": "PloS one",
"author": [
{
"family": "Blomberg",
"given": "Linnea"
},
{
"family": "Raba",
"given": "Leonora"
},
{
"family": "Bengzon",
"given": "Johan"
},
{
"family": "Osther",
"given": "Kurt"
},
{
"family": "Nittby Redebrandt",
"given": "Henrietta"
}
],
"container-title-short":
"volume": "21",
"issue": "5",
"page": "e0349101",
"DOI": "10.1371/
"PMID": "42139305",
"PMCID": "PMC13178988",
"ISSN": "1932-6203",
"publisher": "PLOS",
"URL": "https://
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
15
]
]
}
}
Similar papers
The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.
- [1] doi:10.3390/biomedicines14081702 [code]
- Complement-Targeted Therapies in Glioblastoma: A Systematic Review.Journal: BiomedicinesIn common: other condition, 6 references
- [2] doi:10.3390/biology15141179
- Transcriptomic Evidence Identifies Two TMBIM Subgroups with Opposing Prognostic Associations in Glioma.Journal: BiologyIn common: genetics / omics, other condition, 2 references
- [3] doi:10.3390/ijms27167240
- 1-Piperidine Propionic Acid Inhibits PAR2/
SerpinB3 Signaling and Reduces Glioblastoma Tumor Aggressiveness. Journal: International journal of molecular sciencesIn common: other condition, cellular / molecular, 2 references - [4] doi:10.1177/11769351261460625
- GFAP-Dependent Transcriptional Dynamics and Cellular Heterogeneity in Primary, Recurrent, and Grade III Gliomas.Journal: Cancer informaticsIn common: genetics / omics, other condition, cellular / molecular, 1 reference
- [5] doi:10.3390/cancers18132092
- TGFB2 as a Prognostic Biomarker Associated with Myeloid-Enriched, Multi-Checkpoint-Activat
ed Immunosuppression in Diffuse Glioma: A Multi-Cohort Transcriptomic Study. Journal: CancersIn common: genetics / omics, other condition, 1 reference - [6] doi:10.1111/jcmm.71154
- Mitophagy-Oxidative Stress Molecular Subtypes Define an Immunosuppressive Ecosystem and Vulnerabilities in Glioblastoma.Journal: Journal of cellular and molecular medicineIn common: genetics / omics, other condition, 1 reference
- [7] doi:10.1038/s41467-026-74058-0
- IQGAP3 bridges matrix stiffness with glioma stem cell maintenance and radioresistance by stabilizing SOX2.Journal: Nature communicationsIn common: other condition, cellular / molecular, 1 reference
- [8] doi:10.1186/s12967-026-08385-7
- Dihydrotanshinone I as a novel signal transducer and activator of transcription 3 inhibitor for glioblastoma treatment.Journal: Journal of translational medicineIn common: other condition, cellular / molecular, 1 reference
- [9] doi:10.1186/s13293-026-00927-4 [code]
- Gene regulatory network analysis identifies dysregulation of hypoxia pathways as contributing to glioblastoma treatment resistance in females.Journal: Biology of sex differencesIn common: other condition, cellular / molecular, 1 reference
- [10] doi:10.1038/s41467-026-72746-5
- Non-lytic viral immunotherapy induces long-term glioblastoma survival and tumor-specific immunity without eliciting an antiviral response.Journal: Nature communicationsIn common: other condition, cellular / molecular, 1 reference
Contribute
The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.
Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.
Claim this paper
Correct its record
Say what each link of this record is, remove the ones that are not the paper's, add the ones that are missing. The correction becomes a new version of the record, in its Versions section.
Request its removal
To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).
Discussion, reproductions, activity
Discussion: questions and error reports about this paper and its code, from signed-in readers and its authors. It opens with sign-in.
Reproductions: reports from readers who ran the authors' code: what they reproduced, with which environment, commit and data. It opens with sign-in.
Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.
